Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 91-100 of 411 for multiple

Edit search filters
  1. A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  3. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

    Scottsdale/Phoenix, AZ

  4. Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma

    Scottsdale/Phoenix, AZ

  6. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  7. Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  8. A Study Evaluating the Safety and Effectiveness of UCART Targeting CS1 in Patients with Relapsed/Refractory Multiple Myeloma (MELANI-01)

    Rochester, MN

  9. Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

    Jacksonville, FL

  10. Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer